Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

A robust circular RNA-based prognostic signature for postoperative recurrence in stage II/III colon cancer

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China

  Figure/Table
  Supplementary
  Article Metrics

Citation: Ji Ruan. A robust circular RNA-based prognostic signature for postoperative recurrence in stage II/III colon cancer. AIMS Genetics, 2019, 6(4): 67-69. doi: 10.3934/genet.2019.4.67

References

  • 1. Ferlay J, Colombet M, Soerjomataram I, et al. (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144: 1941–1953.
  • 2. Zhang B, Xie S, Yu I (2018) Differential incidence trends of colon and rectal cancers in Hong Kong: An age-period-cohort analysis. Cancer Commun 38: 42.    
  • 3. Kim NK, Kim YW, Han YD, et al. (2016) Complete mesocolic excision and central vascular ligation for colon cancer: Principle, anatomy, surgical technique, and outcomes. Surg Oncol 25: 252–262.    
  • 4. Schmoll HJ, Van Cutsem E, Stein A, et al. (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23: 2479–2516.
  • 5. Chen T, Huang Y, Wang G (2017) Outcome of colon cancer initially presenting as colon perforation and obstruction. World J Surg Oncol 15: 164.    
  • 6. Peng J, Zhang R, Zhao Y, et al. (2017) Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage III colon cancer. Chin J Cancer. 36: 96.    
  • 7. Dienstmann R, Salazar R, Tabernero J (2015) Personalizing colon cancer adjuvant therapy: Selecting optimal treatments for individual patients. J Clin Oncol 33: 1787–1796.    
  • 8. Yan L, Zhang W (2018) Precision medicine becomes reality-tumor type-agnostic therapy. Cancer Commun 38: 6.    
  • 9. Wilusz JE, Sharp PA (2013) Molecular biology. A circuitous route to noncoding RNA. Science 340: 440–441.
  • 10. Jeck WR, Sorrentino JA, Wang K, et al. (2013) Circular RNAs are abundant, conserved, and associated with ALU repeats. Cold Spring Harbor Lab Press 19: 141–157.
  • 11. Fang L, Du W, Lyu J, et al. (2018) Enhanced breast cancer progression by mutant p53 is inhibited by the circular RNA circ-Ccnb1. Cell Death Differ 25: 2195–2208.    
  • 12. Yang Q, Du WW, Wu N, et al. (2017) A circular RNA promotes tumorigenesis by inducing c-myc nuclear translocation. Cell Death Differ 24: 1609–1620.    
  • 13. Zhang M, Zhao K, Xu X, et al. (2018) A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma. Nature Commun 9: 4475.    
  • 14. Meng S, Zhou H, Feng Z, et al. (2017) CircRNA: Functions and properties of a novel potential biomarker for cancer. Mol Cancer 16: 94.    
  • 15. Ju H, Zhao Q, Wang F, et al. (2019) A circRNA signature predicts postoperative recurrence in stage II/III colon cancer. EMBO Mol Med 2019: e10168.

 

Reader Comments

your name: *   your email: *  

© 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved